Clinical, Epidemiologic, and Therapeutic Characterization of Pediatric Psoriasis in the Costa Rican Social Security System

NCT07451626 — Not yet recruiting, 300 participants, Caja Costarricense de Seguro Social

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Epidemiological and Therapeutic Characterization Study of Psoriatic Disease in Patients Under 18 Years of Age at the Costa Rican Social Security (2018-2025)

Registry	NCT07451626
Status	Not yet recruiting
Study type	Observational
Enrollment	300 (Estimated)
Sponsor	Caja Costarricense de Seguro Social (Other gov)
Conditions	Pediatric Psoriasis
Dates	start 2026-05-01 (estimated), primary completion 2027-05-01 (estimated), completion 2027-05-01 (estimated), first posted 2026-03-05, last updated 2026-04-07
Locations	1 site in Costa Rica

-Summary

The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. The main questions it aims to answer are:

What are the demographic and clinical characteristics of pediatric psoriasis in Costa Rica?

What disease severity profiles, comorbidities, and treatments are observed in routine care?

All patients <18 years with confirmed psoriasis evaluated during the study period will be included. Data will be obtained from electronic health records without intervention or modification of treatment.

Expand all sections · Collapse all

+Detailed description

Pediatric psoriasis is a chronic immune-mediated inflammatory dermatosis associated with physical, psychosocial, and metabolic comorbidity burden beginning early in life. Epidemiologic and clinical data in Latin American pediatric populations remain limited, particularly in real-world care settings. This study is a retrospective observational characterization of pediatric psoriasis patients managed in the Costa Rican Social Security System. Unlike interventional trials or biologic-specific registries, it analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI or pediatric indices), comorbidities, and treatment patterns in routine practice. No therapeutic interventions or standardized follow-up are introduced. By capturing real-world pediatric psoriasis presentation and management in Costa Rica, the study provides baseline national evidence distinct from drug-specific or prospective therapeutic studies.

+Outcome measures

Primary outcomes

Treatment patterns used in pediatric psoriasis in real-world clinical practice (topical, phototherapy, systemic, biologic). [January 2018- December 2025]
Clinical and severity characteristics of pediatric psoriasis, including subtype and severity indices (e.g., PASI/BSA/DLQI or pediatric-adapted measures) documented in routine care. [January 2018- December 2025]
Comorbidity profile in pediatric psoriasis (e.g., metabolic, cardiovascular risk factors, psoriatic arthritis). [January 2018- December 2025]

+Eligibility

Sex: All, ages: any to 18 Years

Inclusion Criteria:

* Patients younger than 18 years at the time of psoriasis diagnosis.
* Clinical diagnosis of psoriasis established by a specialist physician (dermatologist or trained pediatrician) or by a general practitioner within the Costa Rican Social Security System (CCSS).
* Patients evaluated in CCSS healthcare facilities between January 2018 and December 2025.
* Clinical records containing sufficient information on key epidemiologic and therapeutic variables relevant to the study (age, sex, date of diagnosis, clinical subtype, and treatment received).

Exclusion Criteria:

* Patients aged 18 years or older at the time of psoriasis diagnosis.
* Clinical records incomplete or lacking sufficient information for analysis of the main study variables.
* Patients with uncertain or unconfirmed diagnosis of psoriasis.

+Locations (1)

Facility	City	Country	Status
Caja Costarricense del Seguro Social	San José, Provincia de San José	Costa Rica